The National Pharmaceutical Pricing Authority (NPPA) committee the suggested the retail price of each uncoated tablet containing Dexamethasone IP 6 mg for Cadila Healthcare Ltd (manufacturer) and Zydus healthcare Ltd (marketers) as Rs.3.36 per tablet excluding GST.
The recommendation was made by the multidisciplinary committee of experts at the 31st meeting held on April 27 2012. The issue of the retail price fixation of each uncoated tablet containing dexamethasone IP 6 mg manufactured by Cadila Healthcare Ltd. and marketed by Zydus healthcare Ltd. under para 5 of the DPCO, 2013 was addressed during the meeting.
Dexamethasone a type of corticosteroid medication that has anti-immunosuppressant effects and is widely used in rheumatic disorders, skin related disorders, etc.
Dexamethasone is also recommended by the national health in the UK and the national institute of health (NIH) in the US for patients who are suffering from severe COVID – 19 and need either mechanical ventilation or supplement oxygen (without ventilation). Dexamethasone is otherwise not suggested.